100 related articles for article (PubMed ID: 11595504)
1. Pharmacokinetic profile of 3beta-hydroxy-17-(1H-1,2,3-triazol-1-yl)androsta-5,16-diene (VN/87-1), a potent androgen synthesis inhibitor, in mice.
Nnane IP; Njar VC; Brodie AA
J Steroid Biochem Mol Biol; 2001 Sep; 78(3):241-6. PubMed ID: 11595504
[TBL] [Abstract][Full Text] [Related]
2. Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model.
Handratta VD; Jelovac D; Long BJ; Kataria R; Nnane IP; Njar VC; Brodie AM
J Steroid Biochem Mol Biol; 2004 Oct; 92(3):155-65. PubMed ID: 15555909
[TBL] [Abstract][Full Text] [Related]
3. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumour effects and pharmacokinetic profile of 17-(5'-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis.
Nnane IP; Long BJ; Ling YZ; Grigoryev DN; Brodie AM
Br J Cancer; 2000 Jul; 83(1):74-82. PubMed ID: 10883671
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of novel inhibitors of androgen synthesis after intravenous administration in mice.
Nnane IP; Njar VC; Brodie AM
Cancer Chemother Pharmacol; 2003 Jun; 51(6):519-24. PubMed ID: 12715204
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.
Vasaitis T; Belosay A; Schayowitz A; Khandelwal A; Chopra P; Gediya LK; Guo Z; Fang HB; Njar VC; Brodie AM
Mol Cancer Ther; 2008 Aug; 7(8):2348-57. PubMed ID: 18723482
[TBL] [Abstract][Full Text] [Related]
7. Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo.
Grigoryev DN; Long BJ; Nnane IP; Njar VC; Liu Y; Brodie AM
Br J Cancer; 1999 Oct; 81(4):622-30. PubMed ID: 10574247
[TBL] [Abstract][Full Text] [Related]
8. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.
Njar VC; Kato K; Nnane IP; Grigoryev DN; Long BJ; Brodie AM
J Med Chem; 1998 Mar; 41(6):902-12. PubMed ID: 9526564
[TBL] [Abstract][Full Text] [Related]
9. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.
Lopes de Menezes DE; Mayer LD
Cancer Chemother Pharmacol; 2002 Jan; 49(1):57-68. PubMed ID: 11855753
[TBL] [Abstract][Full Text] [Related]
11. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
Klus GT; Nakamura J; Li JS; Ling YZ; Son C; Kemppainen JA; Wilson EM; Brodie AM
Cancer Res; 1996 Nov; 56(21):4956-64. PubMed ID: 8895750
[TBL] [Abstract][Full Text] [Related]
12. Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
Njar VC; Brodie AM
J Med Chem; 2015 Mar; 58(5):2077-87. PubMed ID: 25591066
[TBL] [Abstract][Full Text] [Related]
13. P450-dependent enzymes as targets for prostate cancer therapy.
De Coster R; Wouters W; Bruynseels J
J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
[TBL] [Abstract][Full Text] [Related]
14. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.
Sato N; Gleave ME; Bruchovsky N; Rennie PS; Beraldi E; Sullivan LD
Cancer Res; 1997 Apr; 57(8):1584-9. PubMed ID: 9108464
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.
Bruno RD; Vasaitis TS; Gediya LK; Purushottamachar P; Godbole AM; Ates-Alagoz Z; Brodie AM; Njar VC
Steroids; 2011 Nov; 76(12):1268-79. PubMed ID: 21729712
[TBL] [Abstract][Full Text] [Related]
16. 17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response.
Bruno RD; Gover TD; Burger AM; Brodie AM; Njar VC
Mol Cancer Ther; 2008 Sep; 7(9):2828-36. PubMed ID: 18790763
[TBL] [Abstract][Full Text] [Related]
17. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
18. Effects of novel 17-azolyl compounds on androgen synthesis in vitro and in vivo.
Nnane IP; Njar VC; Liu Y; Lu Q; Brodie AM
J Steroid Biochem Mol Biol; 1999 Dec; 71(3-4):145-52. PubMed ID: 10659703
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice.
Huynh CK; Brodie AM; Njar VC
Br J Cancer; 2006 Feb; 94(4):513-23. PubMed ID: 16449997
[TBL] [Abstract][Full Text] [Related]
20. Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor.
Grigoryev DN; Long BJ; Njar VC; Brodie AH
J Steroid Biochem Mol Biol; 2000 Dec; 75(1):1-10. PubMed ID: 11179903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]